April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Comparison of 2 Doses of Intravitreal Bevacizumab (Avastin) for Proliferative Diabetic Retinopathy: Results From the Pan-American Collaborative Retina Study Group (PACORES) at 24-Month Follow-Up
N. Restrepo; L. Wu; J. G. Sanchez; M. Maia; M. J. Saravia; J. Arevalo; for the Pan-American Collaborative Retina Study Group
Author Affiliations & Notes
  • N. Restrepo
    Retina, Instituto Nacional de Investigacion en Oftalmologia, Medellin, Colombia
  • L. Wu
    Vitreoretinal, Instituto De Cirugia Ocular, San Jose, Costa Rica
  • J. G. Sanchez
    Retina, Instituto Nacional de Investigacion en Oftalmologia, Medellin, Colombia
  • M. Maia
    Retina, the Universidade Federal de São Paulo Instituto da Visão, Sao Paulo, Brazil
  • M. J. Saravia
    Ophthalmology /Retina, Hospital Austral, Buenos Aires, Argentina
  • J. Arevalo
    Retina and Vitreous, Clinica Oftal Centro Caracas, Caracas, Venezuela
  • for the Pan-American Collaborative Retina Study Group
    Retina, Instituto Nacional de Investigacion en Oftalmologia, Medellin, Colombia
  • Footnotes
    Commercial Relationships  N. Restrepo, None; L. Wu, None; J.G. Sanchez, None; M. Maia, None; M.J. Saravia, None; J. Arevalo, None.
  • Footnotes
    Support  in part by the Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4233. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Comparison of 2 Doses of Intravitreal Bevacizumab (Avastin) for Proliferative Diabetic Retinopathy: Results From the Pan-American Collaborative Retina Study Group (PACORES) at 24-Month Follow-Up
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      N. Restrepo, L. Wu, J. G. Sanchez, M. Maia, M. J. Saravia, J. Arevalo, for the Pan-American Collaborative Retina Study Group; Comparison of 2 Doses of Intravitreal Bevacizumab (Avastin) for Proliferative Diabetic Retinopathy: Results From the Pan-American Collaborative Retina Study Group (PACORES) at 24-Month Follow-Up. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4233.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To compare the effects of two doses (1.25 vs 2.5 mg) of intravitreal bevacizumab (Avastin) on retinal neovascularization (RN) in patients with proliferative diabetic retinopathy (PDR)

Methods: : In this interventional, retrospective, multicenter study, we reviewed the clinical records of 39 consecutive patients (43 eyes) with RN due to PDR with a mean age of 54 ± 12.5 years and a follow-up of 24 months. Patients were treated with at least 1 intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab (IVB). Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits

Results: : The mean number of IVB injections per eye was 3.6 ± 1.6 (range: 1 to 7 injections). Twenty-four (55.8%) eyes received IVB at a dose of 1.25 mg, and 19 (44.2%) eyes received a dose of 2.5 mg. Thirty-one eyes (72.1%) had previous panretinal photocoagulation (PRP). In the 1.25 mg group, 8 eyes (33.3%) showed total regression of NVE and 6 eyes (25%) showed total regression of NVD, 5 (20.8%) showed partial regression of NVE and 5 eyes (20.8%) showed partial regression of NVD, and 9 eyes (37.5%) showed no regression of NVE and 13 eyes (54.2%) showed no regression of NVD. In the 2.5 mg group, 7 eyes (36.8%) showed total regression of NVE and 7 eyes (36.8%) showed total regression of NVD, 5 (26.3%) showed partial regression of NVE and 9 eyes (47.4%) showed partial regression of NVD, and 3 eyes (15.8%) showed no regression of NVE and 3 eyes (15.8%) showed no regression of NVD. Comparing the two groups, the difference was not statistically significant considering the number of eyes, which showed NVE regression (P = 0.09) and was statistically significant considering NVD regression (P = 0.005) in favor of the 2.5 mg group

Conclusions: : IVB at doses of 1.25 mg or 2.5 provides total or partial regression of RN associated to PDR in 67.2% of eyes with improvement in BCVA and OCT. There was a statistically significant difference in eyes with more regression of NVD with the 2.5mg dose. No tachyphylaxis was identified at 24 months

Keywords: diabetic retinopathy • retinal neovascularization • vascular endothelial growth factor 
© 2010, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept